Search research articles
Contact Us
Filters
Showing results (41-50 of 49) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 49 results.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
December 3, 2003
[Upper urinary tract tumor: conservative treatment of localized forms]
Jacques Irani, Fabien Saint, Jean-Louis Bonnal, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
March 23, 2005
[Urothelial tumors]
Jacques Irani, Stéphane Bernardini, Jean-Louis Bonnal, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
December 25, 2007
[Urothelial tumors]
Jacques Irani, Stéphane Bernardini, Jean-Louis Bonnal, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 19, 2015
Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial
Pierre Blanchard, Laura Faivre, François Lesaunier, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
May 11, 2007
[The prostate: how to treat this symbol of male vulnerability? An Association Française d'Urologie (AFU)-IPSOS qualitative survey]
Bardon Yves, Alexandre de la Taille, Emmanuel Chartier-Kastler, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 29, 2011
A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial
Karim Fizazi, Francois Lesaunier, Remy Delva, et al.
The Lancet. Oncology
|
June 2, 2015
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial
Karim Fizazi, Laura Faivre, François Lesaunier, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 19, 2026
Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12
Cécile Vicier, Farah Erdogan, Nedjla Allouache, et al.
Clinical Genitourinary Cancer
|
June 1, 2023
Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial
Valentina Orlando, Damien Drubay, Pernelle Lavaud, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 49) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 49 results.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
December 3, 2003
[Upper urinary tract tumor: conservative treatment of localized forms]
Jacques Irani, Fabien Saint, Jean-Louis Bonnal, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
March 23, 2005
[Urothelial tumors]
Jacques Irani, Stéphane Bernardini, Jean-Louis Bonnal, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
December 25, 2007
[Urothelial tumors]
Jacques Irani, Stéphane Bernardini, Jean-Louis Bonnal, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 19, 2015
Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial
Pierre Blanchard, Laura Faivre, François Lesaunier, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
May 11, 2007
[The prostate: how to treat this symbol of male vulnerability? An Association Française d'Urologie (AFU)-IPSOS qualitative survey]
Bardon Yves, Alexandre de la Taille, Emmanuel Chartier-Kastler, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 29, 2011
A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial
Karim Fizazi, Francois Lesaunier, Remy Delva, et al.
The Lancet. Oncology
|
June 2, 2015
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial
Karim Fizazi, Laura Faivre, François Lesaunier, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 19, 2026
Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12
Cécile Vicier, Farah Erdogan, Nedjla Allouache, et al.
Clinical Genitourinary Cancer
|
June 1, 2023
Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial
Valentina Orlando, Damien Drubay, Pernelle Lavaud, et al.
Page
of 5